Darovasertib is under clinical development by Ideaya Biosciences and currently in Phase III for Metastatic Uveal Melanoma. According to GlobalData, Phase III drugs for Metastatic Uveal Melanoma have a 50% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Darovasertib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Darovasertib overview
Darovasertib (IDE-196) is under development for the treatment of metastatic uveal melanoma, uveal melanoma (adjuvant therapy), non-small cell lung cancer, colorectal cancer, pancreatic cancer and cutaneous melanoma. It is administered through the oral route as a tablet formulation. The drug acts by targeting GNAQ/11 mutated protein kinase C. It was also under development for Sturge-Weber syndrome, hepatocellular carcinoma.
Ideaya Biosciences overview
Ideaya Biosciences (Ideaya) is a precision medicine company that develops oncology therapeutics. The company’s product pipeline includes darovasertib (IDE196), a protein kinase C (PKC) inhibitor that targets cancers with GNAQ and GNA11 mutations. Ideaya develops small molecule inhibitors based on synthetic lethality against known and novel targets. It also provides solutions for treating tumors with genetic mutations in homologous recombination deficiency(HRD) and high microsatellite instability (MSI). Ideaya is headquartered in South San Francisco, California, the US.
For a complete picture of Darovasertib’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
